---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-24-000038"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2024-08-05T23:59:59+00:00"
generated_at: "2026-05-31T13:09:31.007983+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Krystal Biotech Q2 revenue $70.3M; net income $15.6M; three pipeline readouts on track

## Summary
- VYJUVEK net product revenue $70.3M in Q2 2024, up 55.3% vs Q1 2024.
- Net income $15.6M ($0.53 diluted EPS) vs net loss ($33.2M) in Q2 2023.
- Cash and investments $628.9M at June 30, 2024; strong balance sheet.
- On track for three clinical data readouts in 2H 2024: KB301 (3Q), KB408 (4Q), KB707 (4Q).
- Received Rare Pediatric Disease Designation for intratumoral KB707 for osteosarcoma in May 2024.

## SEC filing metadata
- accession: 0001711279-24-000038
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2024-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127924000038/0001711279-24-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127924000038/krys-20240805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-24-000038
- JSON: https://secwatch.observer/filing/0001711279-24-000038.json
- Plain text: https://secwatch.observer/filing/0001711279-24-000038.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.